Related by context. All words. (Click for frequent words.) 72 glioma 69 glioblastoma 67 tumors 67 brain tumors 65 ovarian tumors 65 malignant gliomas 64 lymphomas 64 medulloblastoma 64 ependymoma 64 cancers 63 meningiomas 63 adenocarcinoma 63 prostate cancers 63 Glioblastomas 62 glioblastoma multiforme GBM 62 uveal melanoma 62 glioblastomas 62 acoustic neuromas 61 meningioma 61 squamous cell carcinomas 61 GISTs 61 astrocytomas 61 frequently benign tumor 61 neuroblastomas 61 malignancies 60 malignant tumors 60 malignancy 60 carcinomas 60 medulloblastomas 60 anaplastic 59 Glioblastoma 59 grade gliomas 59 metastatic tumors 59 Glioblastoma multiforme GBM 59 pancreatic adenocarcinoma 59 breast cancers 59 lung tumors 59 metastasis 59 bladder cancers 59 leukaemias 59 adenocarcinomas 58 oligodendrogliomas 58 colorectal tumors 58 osteosarcomas 58 neoplasms 58 breast tumors 58 Gliomas 58 carcinoid 58 renal carcinoma 58 melanoma 58 glioma tumors 58 Glioblastoma multiforme 58 pancreatic cancers 58 Wilms tumor 58 invasive ductal 58 pilocytic astrocytomas 58 Follicular lymphoma 58 sarcomatoid 58 GBMs 58 squamous cell cancers 57 squamous cell 57 papillary 57 GBM tumors 57 Glioma 57 breast carcinomas 57 medullary thyroid cancer 57 neoplasia 57 Basal cell 57 metastatic cancer 57 lung adenocarcinoma 57 carcinoma 57 poorer prognosis 57 MALT lymphoma 57 basal cell carcinomas 57 oropharyngeal cancer 57 EGFR mutations 57 endometrial cancers 57 seminoma 57 breast carcinoma 57 nasopharyngeal carcinoma 57 neuroendocrine tumors 57 astrocytoma 57 nonsmall cell lung cancer 57 Hurthle cell 57 ependymomas 57 squamous cell cancer 57 grade glioma 57 neoplasm 57 prostate adenocarcinoma 57 sarcomas 57 squamous cell carcinoma SCC 56 epithelial tumors 56 HER2 positive cancers 56 NF1 56 WT1 56 hepatocellular carcinoma 56 Barrett esophagus 56 prostate tumors 56 oncoproteins 56 CLL cells 56 hepatocellular carcinoma HCC 56 neuroblastoma 56 CIN3 56 adenoma 56 solid tumors 56 ductal breast cancer 56 glioblastoma multiforme 56 NF kB pathway 56 cisplatin resistant 56 PCa 56 cell lymphomas 56 metastases 56 histological subtype 56 oligodendroglioma 56 ADPKD 56 acute leukemias 56 histologic subtype 56 acoustic neuroma 56 glioma rarer 56 cutaneous melanoma 56 nonmelanoma skin cancers 55 relapsing remitting 55 endocrine tumors 55 HbF 55 tumor 55 pituitary adenomas 55 differentiated thyroid 55 follicular lymphoma 55 seminomas 55 mucinous 55 precursor lesions 55 lobular carcinoma 55 recurrent glioblastoma multiforme GBM 55 myeloid cells 55 renal cell carcinomas 55 BRAF gene 55 Squamous 55 mesotheliomas 55 lung cancers 55 melanomas 55 HER2 receptor 55 basal cell carcinoma BCC 55 soft tissue sarcomas 55 benign tumors 55 malignant melanoma 55 squamous cell carcinoma 55 testicular cancers 55 epithelial cancers 55 gastric cancers 55 serous ovarian cancer 55 gastrointestinal stromal tumor 55 lobular cancer 55 thyroid cancers 55 DCIS 55 tumor cells 55 lymphocytic 55 prostate cancer CaP 55 metastatic lesions 55 ccRCC 55 endometrioid 55 colorectal carcinoma 55 premalignant 55 PCNSL 55 Sjögren syndrome 55 Basal cell carcinoma 55 ovarian cancers 55 gastrointestinal cancers 54 pancreatic tumors 54 lymphoproliferative disorders 54 subependymal giant cell 54 leukemias lymphomas 54 KRAS wild 54 Tumours 54 squamous cell lung cancer 54 glioblastoma tumors 54 cell acute lymphoblastic 54 HNSCC 54 pulmonary metastases 54 Acute lymphoblastic leukemia 54 gastric carcinoma 54 Gleevec resistant 54 grade cervical intraepithelial 54 TMEM#B 54 Metastatic 54 HPV# 54 Malignant gliomas 54 synovial sarcoma 54 atherosclerotic lesions 54 malignant cells 54 renal cell carcinoma 54 neurofibromas 54 neuroendocrine cancers 54 HER2 expression 54 HER2 positive breast cancer 54 ductal cancer 54 acute myelogenous leukemia AML 54 metastatic 54 bowel cancers 54 p# mutations 54 leukemias 54 histologies 54 hepatocellular carcinomas 54 castrate resistant 54 embryonal rhabdomyosarcoma 54 HER2 overexpression 54 lymphoma 54 transitional cell carcinoma 54 epithelial ovarian 54 myeloproliferative disorders 54 lymphoblastic leukemia 54 lymph node metastases 54 non Hodgkin lymphomas 54 Chronic lymphocytic leukemia 54 malignant transformation 54 familial pancreatic cancer 54 sporadic ALS 54 parotid gland tumors 54 renal tumors 54 invasive ductal carcinoma 54 prostate tumor 54 cervical intraepithelial neoplasia 54 Anaplastic 54 metastatic prostate cancer 54 myeloma cells 54 malignant brain 54 malignant neoplasm 53 Cholangiocarcinoma 53 N Myc 53 neoplastic 53 atypical hyperplasia 53 metastatic bladder 53 colorectal cancer CRC 53 Glioblastoma Multiforme GBM 53 mosaicism 53 B lymphocytes 53 BRCA mutations 53 nodular melanoma 53 carcinoid cancer 53 MGUS 53 IDH1 mutation 53 estrogen receptor negative 53 familial ALS 53 pilocytic astrocytoma 53 operable breast cancer 53 B7 H3 53 myelomas 53 papillary thyroid cancer 53 Burkitt lymphoma 53 Tumors 53 CLL 53 urothelial carcinoma 53 metastatic melanomas 53 node metastases 53 imatinib Gleevec 53 Waldenstrom macroglobulinemia 53 BRAF mutations 53 chronic lymphocytic leukemia CLL 53 molecular subtypes 53 BCL#A 53 carcinoid tumors 53 lung metastasis 53 beta thalassemia 53 brain tumor glioblastoma multiforme 53 leukemia ALL 53 frontotemporal dementia 53 neuroblastoma tumors 53 Lymphomas 53 melanoma tumors 53 pleomorphic 53 HER2 positive tumors 53 metastatic gastric 53 BRAF mutation 53 non Hodgkin lymphoma 53 bone metastasis 53 pancreatic ductal adenocarcinoma 53 paragangliomas 53 Meningiomas 53 cervical carcinoma 53 gastrointestinal stromal tumors 53 lung adenocarcinomas 53 malignant prostate 53 micrometastases 53 DLBCL 53 Leukemias 53 TCF#L# 53 EGFR mutation 53 NSCLC 53 malignant lymphoma 53 premalignant lesions 53 GIST 53 IGFBP2 53 brain metastases 53 GIST tumors 53 interferon pathway 53 paraganglioma 52 urothelial cancer 52 gastric adenocarcinoma 52 rhabdomyosarcoma 52 molecular abnormalities 52 bronchogenic carcinoma 52 Papillary 52 myeloid 52 metastatic disease 52 leukemic cells 52 indolent lymphoma 52 tumor metastases 52 Non Hodgkin lymphoma 52 basal cell 52 subtype 52 leiomyosarcoma 52 liver metastases 52 colon tumors 52 SPINK1 52 oesophageal adenocarcinoma 52 vestibular schwannomas 52 esophageal adenocarcinoma 52 BRCA deficient 52 acoustic neuroma benign tumor 52 teratoma 52 subtypes 52 salivary gland tumors 52 recurrent glioblastoma multiforme 52 acute lymphoblastic 52 prostate pancreatic 52 glioblastoma GBM 52 Acute myeloid leukemia 52 oral squamous cell 52 malignant lymphomas 52 myeloproliferative diseases 52 indolent lymphomas 52 NKX2 52 BRCA2 mutation carriers 52 Melanomas 52 mesothelin 52 lung carcinomas 52 colorectal cancers 52 essential thrombocythemia 52 Acoustic neuromas 52 cervical lesions 52 Brain metastases 52 BMPR2 52 PDGF receptor 52 gastrointestinal stromal tumors GISTs 52 distant metastasis 52 basal cell nevus syndrome 52 pheochromocytoma 52 chronic myelogenous leukemia CML 52 Hepatocellular Carcinoma HCC 52 recurrent glioblastoma 52 tyrosine kinase inhibitors 52 primitive neuroectodermal tumors 52 mutated genes 52 anti angiogenic therapy 52 malignant pleural mesothelioma 52 Sarcomas 52 nonmetastatic 52 colorectal cancer 52 mammary cancers 52 tumor suppressor genes 52 Carcinoid tumors 52 leukemia AML 52 trans retinoic acid 52 ApoE4 52 PARP inhibitors 52 oncoprotein 52 alveolar rhabdomyosarcoma 52 estrogen receptor positive 52 heavily pretreated 52 cell carcinoma 52 pheochromocytomas 52 malignant fibrous histiocytoma 52 ductal 52 pre cancerous lesions 52 papillary RCC 52 osteosarcoma 52 atherosclerotic disease 52 Stat5 52 NFkB 52 Smad7 52 GSTP1 52 EGFr 52 basal cell cancers 52 hamartomas 52 colorectal liver metastases 52 ovarian cancer 52 ovarian lung 52 schwannomas 52 FTLD 52 situ LCIS 52 neuroendocrine carcinoma 52 prostate carcinoma 52 liver metastasis 52 squamous 52 glioblastoma cells 52 ovarian carcinoma 52 axillary lymph nodes 52 E cadherin expression 52 DIPG 52 metastatic lung cancer 52 EZH2 52 GNAQ 52 lymphocytic leukemia 52 distant metastases 52 chromosomal rearrangement 52 TGFBR1 * 6A 52 EGFR protein 51 JMML 51 upregulating 51 skin cancers 51 malignant pancreatic 51 mutated KRAS gene 51 basal cell carcinoma 51 PTEN protein 51 papillomas 51 Cryptococcus neoformans 51 tumor progression 51 mediated immunity 51 miRNA genes 51 NF2 51 KRAS mutations 51 small lymphocytic lymphoma 51 micronuclei 51 lymph node metastasis 51 FLT3 51 GRP# 51 PNH patients 51 hematopoietic cancers 51 mammary tumors 51 lymphoid 51 thyroid nodules 51 colorectal gastric 51 Renal cell carcinoma 51 pancreatic NET 51 advanced adenomas 51 Myelodysplastic syndromes MDS 51 leukemia CLL 51 mutations 51 MYCN amplification 51 pre cancerous 51 gastric cancer 51 metastatic neuroendocrine tumors 51 EGFR pathway 51 BRCA mutation carriers 51 lymphoid tissue 51 neurofibroma 51 metastatic renal cell carcinoma 51 hypermethylated 51 nonmelanoma skin cancer 51 chemoresistance 51 EGFR gene 51 ERCC1 51 gastrointestinal stromal tumor GIST 51 cholangiocarcinoma 51 radiosensitivity 51 bladder tumors 51 situ CIS 51 invasive lobular 51 epithelioid 51 Leydig cell 51 Relapsing remitting MS 51 esophageal squamous cell carcinoma 51 lymphatic tissue 51 lung metastases 51 noncancerous cells 51 invasive breast cancer 51 BRCA1 mutations 51 PTEN gene 51 precancerous lesions 51 c MET 51 breast cancer subtypes 51 radiosensitive 51 ErbB2 51 malignant nodules 51 neuroblastoma tumor 51 beta catenin protein 51 acute myeloid leukemia AML 51 ovarian pancreatic 51 castration resistant 51 cancerous tumors 51 rectal cancers 51 myelofibrosis polycythemia vera 51 PSADT 51 lobular breast cancer 51 thyroid tumors 51 candidemia 51 desmoplastic 51 intestinal metaplasia 51 glial tumors 51 polycythemia vera 51 BCR ABL mutations 51 tumor recurrence 51 infiltrative 51 basal cells 51 breast cancer metastasis 51 castration resistant prostate cancer 51 cyclin E 51 chronic periodontitis 51 BCR ABL 51 neoadjuvant therapy 51 follicular thyroid cancer 51 Glioblastoma Multiforme 51 proto oncogene 51 FGFR2 51 follicular lymphomas 51 childhood leukemias 51 lymphoma subtypes 51 vulvar intraepithelial neoplasia 51 PKCi 51 spontaneously regress 51 glioma cells 51 angiosarcoma 51 genetic mutations 51 estrogen receptor ER 51 idiopathic myelofibrosis 51 nasopharyngeal carcinoma NPC 51 HOTAIR 51 GPC5 51 KIT mutations 51 oncogenes 51 invasive ductal breast cancer 51 retinoblastoma 51 aromatase 51 tumoral 50 germinal center 50 NSCLC tumors 50 Pancreatic neuroendocrine tumors 50 V#F mutation 50 testicular germ cell 50 myeloproliferative disorder 50 EGF receptor 50 untreated celiac disease 50 transgene expression 50 pancreatic endocrine 50 K ras mutations 50 metastatic colorectal 50 Barrett mucosa 50 lobular carcinomas 50 neoplastic lesions 50 myelodysplastic syndrome MDS 50 papillary carcinoma 50 EGFRvIII 50 acute myeloid leukemia 50 IFNg 50 ductal adenocarcinoma 50 gene amplification 50 androgen receptor AR 50 chlamydial infection 50 HER2 positive 50 invasive lobular carcinoma 50 HGPS 50 dopamine receptor gene 50 CCR7 50 uterine ovarian 50 bladder carcinoma 50 hepatoma 50 CIN2 50 Medulloblastoma 50 neuroblastoma cells 50 systemic scleroderma 50 malignant growths 50 genotoxic stress 50 cutaneous squamous cell carcinoma 50 haematopoietic 50 precancerous cervical lesions 50 ERBB2 50 chromosomal abnormalities 50 metastatic melanoma 50 histologic subtypes 50 oesophageal cancer 50 malignant melanomas 50 malignant lesions 50 anti angiogenic drugs 50 leukemic stem cells 50 TET2 50 Niemann Pick disease 50 epigenetic mechanisms 50 lymphoid cells 50 pre cancerous growths 50 breast endometrial 50 Peutz Jeghers syndrome 50 CD8 + 50 anaplastic astrocytoma AA 50 lymphocytes 50 HIV Lalezari 50 GVHD 50 colorectal tumor 50 Chronic lymphocytic leukemia CLL 50 somatic mutations 50 telomere lengths 50 pancreatic tumor 50 NKT cells 50 tumor histology 50 ASCUS 50 PARP inhibition 50 Squamous cell 50 anaplastic astrocytoma 50 uPAR 50 acinar cells 50 Malignant melanoma 50 ER alpha 50 IGF1R 50 metastatic kidney 50 C EBP alpha 50 biochemical recurrence 50 pancreatic carcinoma 50 TMPRSS2 ERG 50 chromosomal aberrations 50 inherited mutations 50 thymoma 50 pCR 50 p#INK#a 50 sarcoma 50 malaria parasite Plasmodium falciparum 50 lymphangioleiomyomatosis LAM 50 colorectal polyps 50 Pancreatic cancer 50 epithelia 50 CD# mAb 50 BRCA2 mutations 50 neoplastic cells 50 chemotherapeutic agent 50 EphA2 50 Chronic Lymphocytic Leukemia CLL 50 tumors GIST 50 infantile hemangiomas 50 mammary cells 50 relapsing remitting MS 50 panobinostat 50 Carcinoma 50 malignant 50 progesterone receptor negative 50 ErbB2 positive 50 varices 50 Circulating tumor cells 50 taxane therapy 50 NOMID 50 EGFR inhibitors 50 endostatin 50 HER2 neu 50 vWD 50 metastatic cancers 50 HGPIN 50 preoperative chemotherapy 50 S#A# [002] 50 CIN2 + 50 papillary renal cell carcinoma 50 basal cell cancer 50 squamous cell skin 50 biliary tract cancer 50 stage IIIA 50 primary biliary cirrhosis 50 IDH1 50 cancerous cells 50 mesenchymal cells 50 NOTCH1 50 cell adhesion molecule 50 M1 macrophages 50 LQTS 50 Metastasis 50 antibody mediated 50 SOD2 gene 50 CMV infection 50 flavopiridol 50 lung colorectal 50 myeloid leukemia 50 Testicular cancer 50 contralateral breast 50 esophageal tumors 50 Metastatic melanoma 50 E#F# 50 epithelial ovarian cancer 50 EGFR mutant 50 Hodgkin lymphoma HL 50 immunocompetent 50 VHL gene 50 transferrin receptors 50 Epstein Barr virus EBV 50 lung pancreatic 50 HBeAg negative 50 EpCAM 50 Notch pathway 50 benign moles 50 esophageal cancers 50 anterior uveitis 50 hedgehog pathway 50 skeletal metastases 50 SATB1 50 IDH2 50 carcinoid tumor 50 overexpressed 50 colorectal polyp 50 Hashimoto thyroiditis 50 Medullary thyroid cancer 50 locoregional 50 proliferative diabetic retinopathy 50 hematologic malignancies 50 resectable 50 Mesenchymal 49 hepatic fibrosis 49 malignant glioma 49 urothelial 49 nonalcoholic steatohepatitis NASH 49 MAPK pathway 49 JAK2 49 MC1R 49 B CLL 49 mutant protein 49 acute leukemia 49 HER2 positive metastatic breast 49 mutational status 49 CXCR4 49 gene mutations 49 CDK4 49 gastrointestinal stromal tumors GIST 49 adenomas 49 cytotoxicity 49 normal karyotype 49 common hematologic malignancy 49 ERK signaling 49 neurodegenerative disorder 49 HER2 gene 49 non mutated KRAS 49 mutant p# 49 vWF 49 BRCA1 gene 49 cell carcinomas 49 cyclin D1 49 hypereosinophilic syndrome 49 metastatic malignant 49 hyperplasia 49 non squamous NSCLC 49 PTPN# 49 MGd 49 Hedgehog pathway 49 mTOR inhibitors 49 advanced adenoma 49 autoantibodies 49 MMP inhibitors 49 diabetes mellitus DM 49 benign lesions 49 LRP6 49 APOE4 49 Squamous cell carcinoma 49 P. aeruginosa 49 LRP5 49 metachronous 49 metastatic RCC 49 invasive carcinoma 49 cell lymphoma ALCL 49 MSH2 49 myelodysplastic syndromes 49 colon cancers 49 suppressor gene 49 genetic aberrations 49 intestinal polyps 49 CMV disease 49 neural cells 49 narcolepsy cataplexy 49 inflammatory bowel disease 49 estrogen receptor 49 choriocarcinoma 49 GSTT1 49 vinca alkaloids 49 HCV infection 49 Chronic myeloid leukemia 49 clusterin 49 chromosomal instability 49 KRAS mutations occur 49 beta1 integrin 49 standard chemotherapy regimens 49 myelofibrosis 49 acute lymphoid leukemia 49 lymphoblastic lymphoma 49 lymphocyte 49 DNA methylation patterns 49 juvenile myelomonocytic leukemia 49 CD# antigen 49 transmembrane protein 49 mesenchymal cell 49 Metastases 49 Follicular Lymphoma 49 leukaemic stem cells 49 acute promyelocytic leukemia 49 B Cell Lymphoma 49 lymphoid malignancies 49 granule cells 49 HER2/neu 49 COX2 49 heterozygous 49 systemic lupus erythematosus SLE 49 neuronal stem cells 49 cell adhesion molecules 49 precancerous cervical 49 primitive neuroectodermal tumor 49 variant allele 49 chronic granulomatous disease 49 BRAF V#E mutation 49 caveolin 1 49 tumor subtype 49 malignant cancerous 49 excitatory synapses 49 supratentorial 49 FGFR1 49 hepatocellular cancer 49 graft dysfunction 49 hepatic metastases 49 lung nodules 49 cancer mCRC 49 PIK3CA 49 mutated K ras 49 KRAS oncogene 49 cranial radiation 49 Neural stem cells 49 anaplastic astrocytomas 49 metastatic colon cancer 49 lymph node involvement 49 Malignant Melanoma 49 hematopoietic cells 49 pancreatic lung 49 lesions 49 hormone receptor positive 49 synaptic function 49 pre cancerous lesion 49 ovarian carcinomas 49 missense mutations 49 thyroid carcinoma 49 colorectal adenocarcinoma 49 monoclonal antibody therapies 49 haematological cancers 49 gastrointestinal GI cancers 49 thyroglobulin 49 hCG Beta 49 urothelial bladder cancer 49 cytoreduction 49 penetrance 49 overexpress 49 granzyme B 49 HPV infection 49 EoE 49 lymph nodes 49 BRCA1 mutation 49 KRAS mutant 49 superficial bladder cancer 49 Uterine cancer 49 metaplasia 49 Synovial sarcoma 49 leiomyomas 49 hormone deprivation 49 estrogen receptor progesterone receptor 49 follicular lymphoma FL 49 E cadherin 49 autoantibody 49 pneumococcal strains 49 choroidal melanoma 49 leukaemic cells 49 ruptured aneurysms 49 Neuregulin 1 49 pancreatic cysts 49 mutated BRAF gene 49 oncogenic transformation 49 pulmonary metastasis 49 nonsense mutations 49 enzymatic activity 49 PDGFRA 49 colon pancreatic 49 de novo mutations 49 Merkel cell carcinoma 49 HER2 + 49 Dr. Victor Velculescu 49 metastatic basal cell 49 tumor suppressor gene 49 chronic eosinophilic leukemia 49 infarcts 49 PNET 49 Th2 cells 49 cell signaling pathways 49 hematologic cancers 49 c MYC 49 chemoresistant 49 imatinib resistant 49 pro angiogenic 49 Rectal cancer 49 homozygous familial hypercholesterolemia 49 Akt1 49 Bladder cancer 49 laryngeal cancer 49 MCF7 49 NQO1 49 curative therapy 49 histologic 49 sentinel lymph node biopsy 49 VEGF receptor 49 Moyamoya disease 49 FOXP3 49 allogeneic stem cell 49 Multiple myeloma 49 colorectal carcinomas 49 autologous transplants 49 Chronic myeloid leukemia CML 49 cT3 prostate cancer 49 PKM2 49 hematologic toxicity 49 RET PTC rearrangements 49 Stomach cancer 49 SOD1 49 BRCA2 gene 49 endometrial cancer 49 Adenocarcinoma 49 neurofibromatosis type 49 non metastatic osteosarcoma 49 Acute Myelogenous Leukemia AML 49 acute lymphoblastic leukemia 49 eosinophils 49 metastatic tumor 49 esophagitis 49 cancer 49 myeloproliferative neoplasms 49 ADAM# 49 mesenchymal 49 pathologic 48 pancreatic islet 48 hTERT 48 Cytotoxic T 48 effector function 48 Fragile X gene 48 unresectable stage 48 hypermethylation 48 human leukocyte antigens 48 nonseminoma 48 IDH1 mutations 48 chemotherapeutic regimens 48 K ras 48 Myelofibrosis 48 BRCA2 mutation 48 virulence genes 48 HLA B# 48 trophoblast cells 48 Endometrial cancer 48 cell adhesion 48 BRAF V#E 48 EGFR mutation positive 48 metastatic brain tumor 48 germline mutation 48 acute myeloid 48 VZV 48 microRNA miR 48 mitochondrial fusion 48 intracranial tumors 48 intractable epilepsy 48 PTEN mutations 48 Abeta# 48 indolent NHL 48 uterine cancers 48 invasive cervical cancer 48 liposarcoma 48 neoplasias 48 androgen deprivation 48 Th1 48 PI3K Akt 48 adjuvant therapy 48 SOCS1 48 Oncogenes 48 oncogenesis 48 Cutaneous T 48 HER2 ErbB2 48 alpha synuclein gene 48 tumor subtypes 48 Metastatic colorectal cancer 48 Rhabdomyosarcoma 48 carcinogenesis 48 lymphatic vessels 48 AML acute myeloid 48 transmembrane proteins 48 colorectal neoplasms 48 peritoneal cancer 48 STAT3 48 pediatric acute lymphoblastic 48 hepatitis C genotype 48 hematopoietic malignancies 48 lysosomal storage diseases 48 diabetic nephropathy 48 carbohydrate antigens 48 CMV infections 48 hematologic disorders 48 adhesion molecule 48 genetic alterations 48 xenografts 48 IDH mutations 48 PC# cells 48 myelodysplastic syndromes MDS 48 FDG uptake 48 breast cancer gene mutation 48 E selectin 48 cells hESCs 48 kidney urologic 48 transthyretin 48 uterine tumors 48 S. aureus infections 48 granulocytes